Online Brokerage Longbridge Kicks off Hong Kong Market Operations
HONG KONG, Oct 18, 2021 – (ACN Newswire) – Longbridge (“Longbridge” or the “Company”), a…
HONG KONG, Oct 18, 2021 – (ACN Newswire) – Longbridge (“Longbridge” or the “Company”), a…
Investment builds on Antin’s history of investing in renewable energy platforms and supporting the transition…
SINGAPORE, Oct 18, 2021 – (ACN Newswire) – SonicWall, a global leader in physical, virtual…
SINGAPORE / WUHAN, CHINA, Oct 18, 2021 – (ACN Newswire) – To achieve its Five-Year…
WUHAN, CHINA, Oct 18, 2021 – (ACN Newswire) – The 2021 Global Digital Trade Conference…
ATLANTA, GA / ACCESSWIRE / October 17, 2021 / Entrepreneur Kenney Conwell introduces MyMoneyEDU.com, a…
LOS ANGELES, CA / ACCESSWIRE / October 17, 2021 / The ongoing coronavirus outbreak is…
Windsor, Colorado–(Newsfile Corp. – October 16, 2021) – Today, Liquid Craft has announced the launch…
Windsor, Colorado–(Newsfile Corp. – October 16, 2021) – Today, Liquid Craft has announced the launch…
The four-day, in-person event features nearly 600 speakers whose expertise and creativity are reinventing health,…
ROTTERDAM, NETHERLANDS / ACCESSWIRE / October 16, 2021 / The Netherlands has become one of…
LOS ANGELES, CA / ACCESSWIRE / October 16, 2021 / In marketing, it is easier…
SAN JUAN, PUERTO RICO / ACCESSWIRE / October 15, 2021 / In 2020, the global…
VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / Happy Supplements Inc. (CSE:HAPY)(FWB:0I5) (WKN: A2QK6P)…
RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp. (TSX:HBP) (“Helix”…
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) – Enochian BioSciences, a company…
CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company…
– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells…
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients…